reports
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Year-End Rally to Continue? The broad equity market has been on an absolute tear since we discussed in our 10/31/23 Compass how risk/reward favored buyers as key supports were being tested, including 4165 on the S&P 500, $162-$163 on the Russell 2000 (IWM), and $350 on the Nasdaq 100 (QQQ). Furthermore, we discussed in our 11/7/23 Compass our belief that this was more than just another counter-trend rally, and that it is likely the start of a significant year-end rally. We also reiterated our b...
TLYS TILLYS
LOPE GRAND CANYON EDUCATION INC.
LINC LINCOLN EDUCATIONAL SERVICES
GPS GAP INC.
ENSG ENSIGN GROUP INC.
BKE BUCKLE INC.
ATRA ATARA BIOTHERAPEUTICS INC
ANF ABERCROMBIE & FITCH CO. CLASS A
AEO AMERICAN EAGLE OUTFITTERS INC.
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
VRA VERA BRADLEY INC.
ATGE ADTALEM GLOBAL EDUCATION INC.
AFYA AFYA
APELY ALPS ALPINE
PRDO PERDOCEO EDUCATION CORP
LRN STRIDE INC
NHC NHC COMMUNICATIONS
DUOL INC.
EDU DUOLINGO INC
NEW ORIENTAL EDUCATION & TECHNOLOGY GROUP INC.
- Jonathan Moreland
CEM CLEARBRIDGE ENERGY MLP FUND INC.
STAA STAAR SURGICAL CO.
SEDG SOLAREDGE TECHNOLOGIES INC.
PRGO PERRIGO CO. PLC
OPK OPKO HEALTH INC.
MTDR MATADOR RESOURCES COMPANY
INTC INTEL CORPORATION
HRTX HERON THERAPEUTICS INC
EMR EMERSON ELECTRIC CO.
CNP CENTERPOINT ENERGY INC.
ATRA ATARA BIOTHERAPEUTICS INC
ASA ASA
EVA ENVIVA PARTNERS LP
PETS PETMED EXPRESS INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
HAIN THE HAIN CELESTIAL GROUP
NXJ INC.
DMLP NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
TALO DORCHESTER MINERALS L.P.
SNCR TALOS ENERGY INC.
INTZ SYNCHRONOSS TECHNOLOGIES
BW INC.
KSM INTRUSION
CTVA BABCOCK & WILCOX ENTERPRISES
PTON DWS STRATEGIC MUNICIPAL INCOME TRUST
GRWG CORTEVA
VTN INC.
ADV PELOTON INTERACTIVE
ZNTL INC.
BALY GROWGENERATION
CTOS INVESCO TRUST FOR INVESTMENT G
FTCI ADVANTAGE SOLUTIONS INC (A)
MPA ZENTALIS PHARMACEUTICALS
PCT BALLYS CORPORATION
EMO CUSTOM TRUCK ONE SOURCE
MOVE INC.
ET FTC SOLAR
HYLN INC.
GATO BLACKROCK MUNIYIELD PENNSYLVANIA FD
PURECYCLE TECHNOLOGIES INC
CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
MOVANO INC
ENERGY TRANSFER LP
HYLIION HOLDINGS CORP.
SUNSHINE SILVER MINING AND REFINING CORP
- Jonathan Moreland
ATRA ATARA BIOTHERAPEUTICS INC
FLL FULL HOUSE RESORTS INC.
TALO
CTVA TALOS ENERGY INC.
ADV CORTEVA
CTOS INC.
GEG ADVANTAGE SOLUTIONS INC (A)
FTCI CUSTOM TRUCK ONE SOURCE
JANX INC.
PCT GREAT ELM GROUP INC
MOVE FTC SOLAR
ET INC.
JANUX THERAPEUTICS INC
PURECYCLE TECHNOLOGIES INC
MOVANO INC
ENERGY TRANSFER LP
Atara Biotherapeutics Inc: 3 directors
A director at Atara Biotherapeutics Inc bought 270,000 shares at 0.253USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TSLA TESLA INC
RYAM RAYONIER ADVANCED MATERIALS INC
RM REGIONAL MANAGEMENT CORP
PLCE CHILDREN'S PLACE INC.
NUAN NUANCE COMMUNICATIONS INC.
MTSC MTS SYSTEMS CORPORATION
MTRX MATRIX SERVICE COMPANY
LB L BRANDS INC.
INGN INOGEN INC.
FOSL FOSSIL GROUP INC.
FFIC FLUSHING FINANCIAL CORP.
DVN DEVON ENERGY CORPORATION
CREE CREE INC.
BGFV BIG 5 SPORTING GOODS CORP.
AXTI AXT INC.
ATRA ATARA BIOTHERAPEUTICS INC
FLR FLUOR CORPORATION
VSEC VSE CORP
IIIN INSTEEL INDUSTRIES INC.
FREJA VERISEC AB
HP HELMERICH & PAYNE INC.
OESX ORION ENERGY SYSTEMS INC.
OII OCEANEERING INTERNATIONAL INC.
SPWR SUNPOWER CORPORATION
WPX WPX ENERGY INC.
AGYS AGILYSYS INC.
RVP RETRACTABLE TECHNOLOGIES INC.
LCUT LIFETIME BRANDS
WNDW SOLARWINDOW TECHNOLOGIES INC
FUV ARCIMOTO
ROKU ROKU INC. CLASS A
APPN APPIAN
RIOT RIOT BLOCKCHAIN
CDLX CARDLYTICS INC
VVPR VIVOPOWER INTERNATIONAL
LASR NLIGHT
SONO SONOS
INTZ INTRUSION
HYRE HYRECAR
KOD KODIAK SCIENCES
SOLO ELECTRAMECCANICA VEHICLES
FCEL FUELCELL ENERGY INC.
CRNC CERENCE
REZI RESIDEO TECHNOLOGIES INC.
TCON TRACON PHARMACEUTICALS
ACCD ACCOLADE
SPCE VIRGIN GALACTIC HOLDINGS (A)
ALXO ALX ONCOLOGY HOLDINGS
AYRO AYRO INC
NBR NABORS INDUSTRIES LTD.
MGNI MAGNITE INC
VTRS VIATRIS INC.
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
XHR XENIA HOTELS & RESORTS INC.
TGI TRIUMPH GROUP INC.
SRT STARTEK INC.
SIG SIGNET JEWELERS LIMITED
RYAM RAYONIER ADVANCED MATERIALS INC
PLCE CHILDREN'S PLACE INC.
PEB PEBBLEBROOK HOTEL TRUST
PANW PALO ALTO NETWORKS INC.
OLLI OLLIE'S BARGAIN OUTLET HOLDINGS INC
NSTG NANOSTRING TECHNOLOGIES
MSGN MSG NETWORKS INC. CLASS A
M MACY'S INC
KSS KOHL'S CORPORATION
JWN NORDSTROM INC.
INSM INSMED INCORPORATED
FOSL FOSSIL GROUP INC.
DMRC DIGIMARC CORPORATION
CLDT CHATHAM LODGING TRUST
CDNA CAREDX INC
BCO BRINK'S COMPANY
AXTI AXT INC.
AVID AVID TECHNOLOGY INC.
ATRA ATARA BIOTHERAPEUTICS INC
SKY SKYLINE CHAMPION CORPORATION
PZN PZENA INVESTMENT MANAGEMENT
MEG. MEG ENERGY CORP.
MDP MED PAPER S.A.
DVN DEVINE
DRH DIAMONDROCK HOSPITALITY COMPANY
NRP NATURAL RESOURCE PARTNERS L.P.
OXM OXFORD INDUSTRIES INC.
PVH PVH CORP.
RL RALPH LAUREN CORPORATION CLASS A
SHSP SHARPSPRING
VRA VERA BRADLEY INC.
RVP RETRACTABLE TECHNOLOGIES INC.
LCUT LIFETIME BRANDS
TTD TRADE DESK INC. CLASS A
FNKO FUNKO CLASS A
RBBN RIBBON COMMUNICATIONS
RIOT RIOT BLOCKCHAIN
EHC ENCOMPASS HEALTH CORPORATION
RCKT ROCKET PHARMACEUTICALS
APLS APELLIS PHARMACEUTICALS
BLNK BLINK CHARGING
UPWK UPWORK
FKWL FRANKLIN WIRELESS CORP.
HYRE HYRECAR
CPRI CAPRI HOLDINGS LIMITED
GSL GLOBAL SHIP LEASE INC. CLASS A
VEL VELOCITY FINANCIAL INC
DAC DANAOS
VLDR VELODYNE LIDAR INC
GBTC GRAYSCALE BITCOIN TRUST (BTC)
CHX CHAMPIONX CORPORATION
FUBO FUBOTV
GII SPDR S&P GLOBAL INFRASTRUCTURE
SLQT SELECTQUOTE
TCRR INC.
GMDA TCR2 THERAPEUTICS
INC.
GAMIDA CELL LTD
- Dave Nicoski
- Ross LaDuke
BSX BOSTON SCIENTIFIC CORPORATION
SIX SIX FLAGS ENTERTAINMENT CORPORATION
DAL DELTA AIR LINES INC.
VHI VALHI INC.
TLYS TILLYS
1AMQ TEXTAINER GROUP HOLDINGS LIMITED
TDS TELEPHONE AND DATA SYSTEMS INC.
SPNE SEASPINE HOLDINGS CORP.
RNET RIGNET
RGA REINSURANCE GROUP OF AMERICA INCORPORATED
PSA PUBLIC STORAGE
OEC ORION ENGINEERED CARBONS SA
NVCR NOVOCURE LTD.
MOS MOSAIC COMPANY
MGPI MGP INGREDIENTS INC.
MDT MEDTRONIC PLC
GPC GENUINE PARTS COMPANY
FOSL FOSSIL GROUP INC.
EXPE EXPEDIA GROUP INC.
EMN EASTMAN CHEMICAL COMPANY
CE CELANESE CORPORATION
ATRA ATARA BIOTHERAPEUTICS INC
ANF ABERCROMBIE & FITCH CO. CLASS A
AEO AMERICAN EAGLE OUTFITTERS INC.
ADMS ADAMAS PHARMACEUTICALS INC.
G2O GOLAR LNG LIMITED
DLTH DULUTH HOLDINGS INC. CLASS B
DRI DARDEN RESTAURANTS INC.
LYV LIVE NATION ENTERTAINMENT INC.
VRA VERA BRADLEY INC.
WMB WILLIAMS COMPANIES INC.
USM UNITED STATES CELLULAR CORP
AFI ARMSTRONG FLOORING INC.
DFIN DONNELLEY FINANCIAL SOLUTIONS INC.
ARCH ARCH RESOURCES INC. CLASS A
FTV FORTIVE CORP.
WRK WESTROCK COMPANY
GM GENERAL MOTORS COMPANY
LBRT LIBERTY OILFIELD SERVICE
ST SENSATA TECHNOLOGIES HOLDING PLC
SPB SPECTRUM BRANDS HOLDINGS INC.
NXGN NEXTGEN HEALTHCARE INC.
MEC MAYVILLE ENGINEERING
KTB KONTOOR BRANDS
ALRS ALERUS FINANCIAL CORP.
FBRX FORTE BIOSCIENCES INC
VTOL BRISTOW GROUP
INC.
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Fina...
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress Company to host conference call today at 8:00 a.m. EST SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and recent business highlights. “2019 was a ye...
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing R...
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to Kristin Yarema, its Chief Commercial Officer. The compensation committee of Atara’s board of directors granted Ms. Yarema a stock option to purchase 110,000 shares of Atara’s common stock effective as of...
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferen...
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon, the Company's President and Chief Executive Officer, will participate at two upcoming investor conferences in March: Cowen 40th Annual Health Care ConferenceFireside Chat: Monday, March 2, 2020 at 4:10 pm ESTBoston Marriott Co...
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Fi...
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 Live Conference Call and Webcast at 8:00 a.m. EST SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the Company will release fourth quarter and full year 2019 financial results before the market opens on Thursday, February 27, 2020. Following the releas...
Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer
Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today named Kristin Yarema as Chief Commercial Officer, effective as of February 18, 2020. Dr. Yarema has more than 20 years of biopharmaceutical experience during which she has led product strategy and commercialization for therapies at all stages of their lif...
Atara Biotherapeutics to Present 2020 Key Milestones and Progress in B...
Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference Key milestones anticipated across Atara’s four strategic priorities in 2020 Continued investment in EBV T-cell platform to develop off-the-shelf, allogeneic CAR T immunotherapies leveraging favorable EBV T-cell safety, expansion, trafficking and persistence characteristics SOUTH SAN FRANCISCO, Calif., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading of...
Atara Biotherapeutics Reports Updated Long-Term Clinical Results from ...
Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting 61 patients with diverse EBV-associated diseases, including 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® (tabelecleucel) EAP study Tab-cel® was generally well-tolerated in all patients with EBV+ PTLD and other EBV-associated diseases Estimated two-year overall...
Atara Biotherapeutics to Participate at Evercore ISI Second Annual Hea...
Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon, the Company's President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI Second Annual HealthCONx Conference on Tuesday, December 3, 2019 at 3:50 p.m. EST. The conference will ...
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results a...
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the third quarter of 2019 and recent business highlights. “I am pleased with our recent clinical, operational and strategic progress,” said Pascal Touchon, President and Chi...
Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes...
Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® EAP study including a subgroup of 22 patients who would have likely met eligibility criteria for Atara’s ongoing tab‑cel® Phase 3 studiesAn overall response rate (ORR) of 55 and 82 percent was observed in this subgroup of ...
Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progr...
Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019 Live Conference Call and Webcast at 8:00 a.m. EST SOUTH SAN FRANCISCO, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that its third quarter 2019 operational progress and financial results will be released before the market opens on Thursday, November 7, 2019....
Atara Biotherapeutics Announces Executive Departures
Atara Biotherapeutics Announces Executive Departures SOUTH SAN FRANCISCO, Calif., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the departures of Dr. Christopher Haqq, Chief Scientific Officer, and Mina Kim, General Counsel and Head of Corporate Strategy. “I want to thank Chris and Mina for their significant contributions to Atara,” said Pascal Touchon, President and Chief Executive Officer ...
Atara Biotherapeutics Reports Early Findings of Potential Efficacy fro...
Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019 Enrollment in the fourth and final planned Phase 1 dose escalation cohort completed ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, believed to play a role in the pathogenesis of multiple sclerosis Conference call and webcast today at 3:30 p.m. CEST / 9:30 a.m. EDT SOUTH SAN FRANCISCO, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immun...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.